Robertson JFR, Paridaens RJ, Lichfield J, Bradbury I, et al. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. Eur J Cancer 2021;145:19-28.
PMID: 33418233